Nonparametric Bayesian Policy Priors for Reinforcement Learning

We consider reinforcement learning in partially observable domains where the agent can query an expert for demonstrations. Our nonparametric Bayesian approach combines model knowledge, inferred from expert information and independent exploration, with policy knowledge inferred from expert trajectories. We introduce priors that bias the agent towards models with both simple representations and simple policies, resulting in improved policy and model learning

Infinite dynamic bayesian networks

We present the infinite dynamic Bayesian network model (iDBN), a nonparametric, factored state-space model that generalizes dynamic Bayesian networks (DBNs). The iDBN can infer every aspect of a DBN: the number of hidden factors, the number of values each factor can take, and (arbitrarily complex) connections and conditionals between factors and observations. In this way, the iDBN generalizes other nonparametric state space models, which until now generally focused on binary hidden nodes and more restricted connection structures. We show how this new prior allows us to find interesting structure in benchmark tests and on two realworld datasets involving weather data and neural information flow networks.Massachusetts Institute of Technology (Hugh Hampton Young Memorial Fund Fellowship)United States. Air Force Office of Scientific Research (AFOSR FA9550-07-1-0075

Study, Survey and Analysis for Media Selection

This paper is a literature review on practical techniques and rules using PowerPoint, animation, and video effectively for instruction. Instruction may be teaching, training, coaching, tutoring, schooling etc. This paper must be of awareness to mentors and instructional technology staff who support faculty members in the development of instructional media. Main objective of this paper is to identify and select the proper technologies for enhancing a particular pedagogy or learning goal. Choose media that support instructor's activity

Palladium nanoparticles by electrospinning from poly(acrylonitrile-co-acrylic acid)-PdCl2 solutions. Relations between preparation conditions, particle size, and catalytic activity

Catalytic palladium (Pd) nanoparticles on electrospun copolymers of acrylonitrile and acrylic acid (PAN-AA) mats were produced via reduction of PdCl2 with hydrazine. Fiber mats were electrospun from homogeneous solutions of PAN-AA and PdCl2 in dimethylformamide (DMF). Pd cations were reduced to Pd metals when fiber mats were treated in an aqueous hydrazine solution at room temperature. Pd atoms nucleate and form small crystallites whose sizes were estimated from the peak broadening of X-ray diffraction peaks. Two to four crystallites adhere together and form agglomerates. Agglomerate sizes and fiber diameters were determined by scanning and transmission electron microscopy. Spherical Pd nanoparticles were dispersed homogeneously on the electrospun nanofibers. The effects of copolymer composition and amount of PdCl2 on particle size were investigated. Pd particle size mainly depends on the amount of acrylic acid functional groups and PdCl2 concentration in the spinning solution. Increasing acrylic acid concentration on polymer chains leads to larger Pd nanoparticles. In addition, Pd particle size becomes larger with increasing PdCl2 concentration in the spinning solution. Hence, it is possible to tune the number density and the size of metal nanoparticles. The catalytic activity of the Pd nanoparticles in electrospun mats was determined by selective hydrogenation of dehydrolinalool (3,7-dimethyloct-6- ene-1-yne-3-ol, DHL) in toluene at 90 °C. Electrospun fibers with Pd particles have 4.5 times higher catalytic activity than the current Pd/Al2O3 catalyst

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

BACKGROUND: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide. OBJECTIVES: To describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all clinical study reports of published and unpublished randomised, placebo-controlled trials and regulatory comments. SEARCH METHODS: We searched trial registries, electronic databases (to 22 July 2013) and regulatory archives, and corresponded with manufacturers to identify all trials. We also requested clinical study reports. We focused on the primary data sources of manufacturers but we checked that there were no published randomised controlled trials (RCTs) from non-manufacturer sources by running electronic searches in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE (Ovid), EMBASE, Embase.com, PubMed (not MEDLINE), the Database of Reviews of Effects, the NHS Economic Evaluation Database and the Health Economic Evaluations Database. SELECTION CRITERIA: Randomised, placebo-controlled trials on adults and children with confirmed or suspected exposure to naturally occurring influenza. DATA COLLECTION AND ANALYSIS: We extracted clinical study reports and assessed risk of bias using purpose-built instruments. We analysed the effects of zanamivir and oseltamivir on time to first alleviation of symptoms, influenza outcomes, complications, hospitalisations and adverse events in the intention-to-treat (ITT) population. All trials were sponsored by the manufacturers. MAIN RESULTS: We obtained 107 clinical study reports from the European Medicines Agency (EMA), GlaxoSmithKline and Roche. We accessed comments by the US Food and Drug Administration (FDA), EMA and Japanese regulator. We included 53 trials in Stage 1 (a judgement of appropriate study design) and 46 in Stage 2 (formal analysis), including 20 oseltamivir (9623 participants) and 26 zanamivir trials (14,628 participants). Inadequate reporting put most of the zanamivir studies and half of the oseltamivir studies at a high risk of selection bias. There were inadequate measures in place to protect 11 studies of oseltamivir from performance bias due to non-identical presentation of placebo. Attrition bias was high across the oseltamivir studies and there was also evidence of selective reporting for both the zanamivir and oseltamivir studies. The placebo interventions in both sets of trials may have contained active substances. Time to first symptom alleviation. For the treatment of adults, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% confidence interval (CI) 8.4 to 25.1 hours, P 1000) and nausea whilst on treatment (RD 4.15%, 95% CI 0.86 to 9.51); NNTH = 25 (95% CI 11 to 116). AUTHORS' CONCLUSIONS: Oseltamivir and zanamivir have small, non-specific effects on reducing the time to alleviation of influenza symptoms in adults, but not in asthmatic children. Using either drug as prophylaxis reduces the risk of developing symptomatic influenza. Treatment trials with oseltamivir or zanamivir do not settle the question of whether the complications of influenza (such as pneumonia) are reduced, because of a lack of diagnostic definitions. The use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children. The lower bioavailability may explain the lower toxicity of zanamivir compared to oseltamivir. The balance between benefits and harms should be considered when making decisions about use of both NIs for either the prophylaxis or treatment of influenza. The influenza virus-specific mechanism of action proposed by the producers does not fit the clinical evidence

SOCIO-ECONOMIC IMPACT OF CLINICAL RESEARCH IN VARIOUS COUNTRIES

This article attempts to outline the socio-economic impact of clinical research in sample geographies from around the world. With an attempt, we could sample geographies that largely represent varied population - from developed markets to developing markets, from poor to rich countries, from countries seeing increase in clinical research to countries that are struggling to retain clinical research. In absence of any research/ survey that can map socio economic impact at global level, this article best describes the general trends at least, if not a truly global view. Largely, there are two impacts which are quite visible across all of the sampled geographies. The first one is that the advent of clinical research in any geographies have led to a palpable increase in the standards of medical care in that geographies. This is probably driven by essential training that researchers go through and thereby learning the GCP - Good clinical practice. Another effect is a definite increase in the standards of medical infrastructure, once the clinical research started. This is a reflection of the fact that general population has benefited by investment made by sponsor companies to perform clinical research. The second impact is that the effect of Clinical research activities on economy is also uniformly positive. This results from new job creation that leads to downstream economy. But additionally, it also follows from having healthier humans (those who received medical benefits of clinical trials) who pay more taxes and who further pedals the economy by spending. All in all, the size of these benefits (as measured in various markets) is significant enough not to loose on them and many countries are actively pursuing clinical research to get these benefits

Sprint interval and sprint continuous training increases circulating CD34+ cells and cardio-respiratory fitness in young healthy women

The improvement of vascular health in the exercising limb can be attained by sprint interval training (SIT). However, the effects on systemic vascular function and on circulating angiogenic cells (CACs) which may contribute to endothelial repair have not been investigated. Additionally, a comparison between SIT and sprint continuous training (SCT) which is less time committing has not been made